Dose Finding Trial of Rosuvastatin and Atorvastatin Versus Hepatitis C

This study has been completed.

Sponsored by:	Bader, Ted, M.D.
Information provided by:	Bader, Ted, M.D.
ClinicalTrials.gov Identifier:	NCT00446940

Purpose

Different Doses of rosuvastatin and atorvastatin will be used to see if HCV viral load changes and liver tests change.

Condition	Intervention	Phase
Hepatitis C	Drug: rosuvastatin Drug: atorvastatin	Phase II

MedlinePlus related topics: Hepatitis Hepatitis C

Drug Information available for: Atorvastatin Atorvastatin calcium Rosuvastatin Rosuvastatin calcium

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Official Title:	Dose Finding Trial of Rosuvastatin and Atorvastatin Versus Hepatitis C

Further study details as provided by Bader, Ted, M.D.:

Eligibility

Criteria

Inclusion Criteria:

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00446940

Locations

United States, Oklahoma
VA Hospital
OKlahoma City, Oklahoma, United States, 73104

Sponsors and Collaborators

Bader, Ted, M.D.

Investigators

Principal Investigator:

Ted Bader, MD

VA Medical Center, Oklahoma City, OK

More Information

Study ID Numbers:	13133
Study First Received:	March 11, 2007
Last Updated:	September 8, 2008
ClinicalTrials.gov Identifier:	NCT00446940
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Virus Diseases
Hepatitis
Signs and Symptoms
Liver Diseases
Rosuvastatin

Digestive System Diseases
Hepatitis, Viral, Human
Hepatitis C
Atorvastatin

Additional relevant MeSH terms:

Antimetabolites
RNA Virus Infections
Molecular Mechanisms of Pharmacological Action
Flaviviridae Infections
Therapeutic Uses

Antilipemic Agents
Enzyme Inhibitors
Anticholesteremic Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 16, 2009